Recent Updates
Recently added Catalysts

Pediatric Brain Tumor: one US-listed biotech with a clinical-stage programme

OncologyUncontestedData as of 2026-09-04

Competitors1in the clinic
Median market cap$124Muniverse median $1.20B
Allocated capital$41M$124M competing
Phase 3 or filed00 mid, 1 early
Pure plays0this indication only
Capital rank293/299crowding rank 293

Pediatric Brain Tumor is uncontested. NeOnc Technologies Holdings (NTHI) is the only US-listed developer in the $100M to $20B band running a clinical programme here, with NEO100 in phase 1.

There is no public comparable to price it against. NTHI spreads its $124M market cap across 3 indications, so $41M of it is allocated here.

Nothing here has reached Phase 3: 0 programmes in mid stage and 1 in early stage, so the field is still several years from a first approval.

$41M of allocated capital sits in Pediatric Brain Tumor, ranking it 293rd of 299 indications by the money committed to it.

Companies developing drugs for Pediatric Brain Tumor 1

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
NTHINeOnc Technologies HoldingsNEO100Phase 11$124MNo3 31 Dec 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile.

Why Pediatric Brain Tumor counts as uncontested

Uncontested. One US-listed developer in the size band is running a clinical programme here, so there is no public comparable to price it against.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Pediatric Brain Tumor has one competitor and a median of $124M.

Oncology

Oncology holds $187B of the map's capital, 27.8% of the total, spread across 119 indications and 103 companies. 34 of those indications have more than one company competing.

See every Oncology indication on the map

Related indications in Oncology

Aggressive B-Cell Non-Hodgkin's Lymphoma1 company · $34M · median $168MUncontestedFollicular Lymphoma1 company · $34M · median $168MUncontestedMetastatic Anal Cancer1 company · $51M · median $102MUncontestedMetastatic Pancreatic Adenocarcinoma1 company · $53M · median $371MUncontestedNewly Diagnosed Glioblastoma1 company · $53M · median $371MUncontestedMetastatic Urothelial Cancer1 company · $54M · median $214MUncontestedAdenocarcinoma Lung Cancer; Squamous Cell Lung Carcinoma1 company · $64M · median $129MUncontestedRelapsed or Refractory Multiple Myeloma1 company · $13M · median $203MUncontested

Pediatric Brain Tumor pipeline questions

Which biotech companies are developing drugs for Pediatric Brain Tumor?

NeOnc Technologies Holdings (NTHI, NEO100, Phase 1). Those are the 1 US-listed developer in the $100M to $20B market cap band with a clinical-stage programme in Pediatric Brain Tumor.

How advanced is the Pediatric Brain Tumor pipeline?

Of the 1 clinical-stage programme in Pediatric Brain Tumor, 0 are in Phase 3 or filed, 0 are in mid-stage development and 1 is in early-stage development.

Is anyone else developing a drug for Pediatric Brain Tumor?

No. NTHI is the only US-listed company in the $100M to $20B market cap band with a clinical-stage programme in Pediatric Brain Tumor, which is why the indication is classified as uncontested.

When is the next Pediatric Brain Tumor catalyst?

The next dated catalyst in Pediatric Brain Tumor is NTHI on 31 Dec 2026. 1 dated event across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map